Successful use of tissue plasminogen activator in catheter-related intracardiac thrombus of a premature infant.
The incidence of clinically apparent neonatal thrombosis is about 0.1 to 0.2% in the neonatal intensive care unit (NICU). The optimal treatment modalities for neonates with thromboses are not known. We report on our experience with recombinant tissue type plasminogen activator (rt-PA) in a premature infant with an intracardiac thrombus.
Torres-Valdivieso
M J
MJ
Section of Perinatology, Hospital 12 de Octubre, Madrid, Spain.
Cobas
J
J
Barrio
C
C
Muñoz
C
C
Pascual
M
M
Orbea
C
C
Rodriguez
E
E
Gutiérrez
F
F
D002405:Catheterization, Central Venous / Q000009:adverse effects*; D004200:Diseases in Twins; D004305:Dose-Response Relationship, Drug; D005260:Female; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010960:Plasminogen Activators / Q000008:administration & dosage*; D011247:Pregnancy; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D014463:Ultrasonography
D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator